Antifungal pharmacotherapy for invasive mould infections
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The incidence of invasive mould infections is increasing and is associated with significant morbidity and mortality. Among the most prevalent of these infections are those caused by Aspergillus and Fusarium species. Invasive disease caused by moulds frequently presents as a pulmonary infection, but haematogenous infection can occur. Some moulds cause cutaneous disease through either direct inoculation of the skin or secondary spread to the skin after dissemination from another body site. Early diagnosis can often be difficult and, unfortunately, diagnosis occurs late in the course of illness in many cases. Treatment options have historically been limited by the need for intravenous administration (amphotericin B), significant toxicities (amphotericin B), lack of reliable in vitro activity (e.g., amphotericin B in Fusarium and Scedosporium apiospermum infections) and relative lack of clinical experience with newer agents. The recent approval of voriconazole (Vfend, Pfizer) introduces a treatment option that demonstrates both in vitro and in vivo activity against a variety of moulds. With the recent development of the new echinocandin class of antifungal agents and newer broad-spectrum azole antifungal agents with in vitro mould activity, there is a renewed emphasis on fungal treatment strategies. Antimould therapy presents challenges in adverse effect avoidance and management, drug interactions and pharmacoeconomic considerations. Furthermore, combination therapy is being explored with these various new antifungal agents. The administration of an optimal fungicidal therapy early in the course of the illness and control of the underlying disease are vital to prevent complications and mortality from these tenacious mycoses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
Hughes, W. T., Armstrong, D., Bodey, G. P., Bow, E. J., Brown, A. E., Calandra, T., Feld, R., Pizzo, P. A., Rolston, K. V. I., Shenep, J. L., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/339215 · Cited by 1,964
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844 · cited 8×
“(2003) 4(2) 151 evidence-based data [39,40,51].”
BackgroundResultInfluentialWald, A., Leisenring, W., van Burik, J., & Bowden, R. A. (1997) · The Journal of Infectious Diseases · doi:10.1086/516480 · Cited by 742 · cited 1×
“Haematopoietic transplantation may result in medical complications such as graft versus host disease (GVHD), a disorder requiring intensification of immunosuppressive treatments that is itself a known risk factor for developing invasive fungal infections [9].”
BackgroundAlangaden, G. J., Wahiduzzaman, M., Chandrasekar, P. H., & the Bone Marrow Transplant Group (2002) · Clinical Infectious Diseases · doi:10.1086/342061 · Cited by 45 · cited 3×
“In one study, infections caused by Aspergillus were implicated as the most common cause of community-acquired pneumonia in haematopoietic stem cell transplant patients with GVHD [14].”
Background
Cited by
Lemke, A., Kiderlen, A. F., & Kayser, O. (2005) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-005-1955-9 · Cited by 305
Galgóczy, L., Papp, T., Lukács, G., Leiter, Ã., Pócsi, I., & Vágvölgyi, C. (2007) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2007.00661.x · Cited by 37
Galgóczy, L., Lukács, G., Nyilasi, I., Papp, T., & Vágvölgyi, C. (2010) · Acta Biologica Hungarica · doi:10.1556/abiol.61.2010.3.11 · Cited by 23
In vitro interaction between suramin and fluvastatin against clinically important Zygomycetes
Galgóczy, L., Papp, T., & Vágvölgyi, C. (2009) · Mycoses · doi:10.1111/j.1439-0507.2008.01634.x · Cited by 14
Ezoddin, M., Abdi, K., Behnamipour, S., & Javadi, M. H. S. (2022) · Journal of Separation Science · doi:10.1002/jssc.202100965 · Cited by 12
Metadata
- Authors
- Gallagher, J. C., Ashley, E. S. D., Drew, R. H., & Perfect, J. R.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2003-02
- Volume
- 4
- Issue
- 2
- Pages
- 147-164
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2167567176
- Cited by
- 46
- References
- 5
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antifungal pharmacotherapy for invasive mould infections. https://app.cochat.ai/papers/10.1517/14656566.4.2.147
- The paper
- Gallagher, J. C., Ashley, E. S. D., Drew, R. H., & Perfect, J. R. (2003). Antifungal pharmacotherapy for invasive mould infections. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.4.2.147
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.